> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sarepta Therapeutics Wins Priority Review Voucher
- URL: https://www.fdaweb.com/sarepta-therapeutics-wins-priority-review-voucher/
- Published: 2021-03-12T12:00:00.000Z
- Updated: 2026-09-14T16:50:40.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148868

*Federal Register* notice: FDA has issued a priority review voucher to Sarepta Therapeutics for a qualifying rare pediatric disease product application — Amondys 45 (casimersen). The drug is indicated for treating Duchenne Muscular Dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-03-12/pdf/2021-05208.pdf?ref=fdaweb.com).